Blockchain Registration Transaction Record

GeoVax Partners with CEPI to Advance Mpox Vaccine

GeoVax partners with CEPI to advance GEO-MVA mpox vaccine via independent lab testing, aiming to expand global MVA supply and preparedness.

This news matters because it represents a critical step toward diversifying the global supply of mpox vaccines. Recent outbreaks have exposed vulnerabilities in vaccine availability, often relying on a single manufacturer. By leveraging CEPI's independent laboratory network, GeoVax aims to generate robust data that could lead to regulatory approval of GEO-MVA, offering an additional qualified source of MVA-based vaccines. This could enhance global preparedness, reduce dependency on limited supply chains, and enable faster, more equitable access to vaccines during outbreaks. Moreover, the partnership underscores the importance of standardized, independent evaluation in vaccine development, which can build trust among regulators and the public. As mpox continues to pose a public health threat, especially in regions with limited resources, having multiple vaccine suppliers is essential for effective response and biosecurity.